DCPH Deciphera Pharmaceuticals Inc.

22.17
+0.39  (+2%)
Previous Close 21.78
Open 21.81
Price To Book 3.53
Market Cap 846,502,346
Shares 38,189,052
Volume 24,576
Short Ratio
Av. Daily Volume 230,474

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 additional data due 2H 2019.
DCC-3014
Solid tumors or hematological malignancies
Phase 3 data due mid-2019.
DCC-2618 - INVICTUS
Gastrointestinal Stromal Tumors (GIST) - fourth-line
Phase 1 expansion data due 2019.
DCC-2618
Gastrointestinal Stromal Tumors (GIST)
Phase 3 trial initiation announced December 20, 2018.
DCC-2618 - INTRIGUE
Gastrointestinal Stromal Tumors (GIST) - second-line
Phase 1b trial complete.
Rebastinib
Breast Cancer
Phase 2 part of trial to commence 2Q 2019. Part 1 data due 2H 2019.
Rebastinib and paclitaxel
Solid tumors
Phase 1b/2 trial initiation announced January 3, 2019.
Rebastinib and carboplatin
Solid tumors

Latest News

  1. Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors
  2. Is Deciphera Pharmaceuticals, Inc. (DCPH) A Good Stock To Buy?
  3. Options Traders Expect Huge Moves in Deciphera Pharmaceuticals (DCPH) Stock
  4. Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
  5. Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers
  6. Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Global Healthcare Conference
  7. Deciphera Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference
  8. Deciphera Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results
  9. Here’s What Hedge Funds Think About Deciphera Pharmaceuticals, Inc. (DCPH)
  10. Imagine Owning Deciphera Pharmaceuticals (NASDAQ:DCPH) And Wondering If The 16% Share Price Slide Is Justified
  11. Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results
  12. Market Trends Toward New Normal in Exelon, AT&T, United States Cellular, Deciphera Pharmaceuticals, Boyd Gaming, and Argo Group International — Emerging Consolidated Expectations, Analyst Ratings
  13. Deciphera CEO resigns, Ex-Agios exec to take over
  14. Deciphera Pharmaceuticals, Inc. Announces Retirement of Michael D. Taylor, Ph.D.
  15. Deciphera Pharmaceuticals, Inc. to Present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day
  16. Deciphera Pharmaceuticals Shares March Higher, Can It Continue?
  17. Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
  18. Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors
  19. Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clinical Study with DCC-3014 and an Update on Future Development Plans